Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-209: Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in MIBC
NCT07475806Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of enfortumab vedotin in muscle-invasive bladder cancer (MIBC), sponsored by Astellas Pharma. Started Mar 2026; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07475806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475806.